FDA Grants Priority Review of Melflufen for Patients with Triple-Class Refractory Multiple Myeloma
STOCKHOLM— August 29, 2020— Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides´ New Drug Application...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Food and Drug Administration (FDA) | Grants | Myeloma | New Drug Applications | Pharmaceuticals